Primary open angle glaucoma and ocular hypertension Eye Diseases
Conditions
Interventions
This non-interventional study will observe participants for up to 3 months from the start of their LAT/NET FDC treatment, or until they withdraw consent, switch to another treatment, become pregnant,
Sponsors
Santen (United Kingdom)
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. A diagnosis of primary open-angle glaucoma (POAG) or ocular hypertension (OHT) 2. Patient aged = 18 years 3. Have previously received monotherapy with a prostaglandin analogue or netarsudil which has provided insufficient IOP reduction 4. Patients for whom the decision to initiate treatment with LAT/NET FDC was made as part of routine clinical practice and prior to study inclusion 5. Signed informed patient consent before the start of data collection
Exclusion criteria
Exclusion criteria: 1. Previously received combination therapy of topical IOP-lowering medications (including a fixed dose combination) 2. Patient is pregnant, and/or lactating, or planning pregnancy in the following 3 months 3. Contraindications as listed in the SmPC 4. Participation in an investigational programme with interventions outside of routine clinical practice within 30 days prior to enrolment 5. Previous treatment of the study eye with laser in the last 90 days prior to enrolment 6. Patient is listed for laser treatment in the study eye within the next 90 days after enrolment 7. Has a condition or be in a situation that, in the Investigator’s opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient’s study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure measured using IOP measurements at Baseline, 6 weeks and 3 months | — |
Countries
England, United Kingdom
Contacts
Public ContactJulia Martin
Outcome results
None listed